Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on GitLab, Lowers Price Target to $45

Barclays analyst Ryan Macwilliams maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $65 to $45.
byBenzinga Newsdesk
March 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Ryan Macwilliams maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $65 to $45.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases To Late Discovery Pipeline; Signed An Agreement With Bayer AG To In-License A New Chemical Entity That Emerged From The Companies’ Fibrosis Research Collaboration

By Benzinga Newsdesk
January 4, 9:01 AM
Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that

RXRX